This comprehensive review examines the clinical impact of resmetirom, the first medication approved by the FDA for treating Metabolic Dysfunction-Associated Steatohepatitis (MASH). MASH is a severe form of fatty liver disease that affects up to 30% of people with metabolic dysfunction, often leading to liver fibrosis or cirrhosis. The review synthesizes current clinical guidance and real-world data on resmetirom, a selective thyroid hormone receptor-beta agonist designed to mimic the effects of thyroid hormones specifically in the liver to reduce fat accumulation. Clinical evidence shows that resmetirom successfully achieves both the resolution of MASH and the improvement of liver scarring (fibrosis) in non-cirrhotic patients. The drug is generally safe and well-tolerated, with treatment response appearing independent of traditional weight-loss therapies. A notable limitation is that it is not recommended for patients who have already progressed to full cirrhosis or those with untreated thyroid disorders.
This scoping review evaluated the real-world effectiveness of front-of-pack nutritional warning labels implemented in Peru. Researchers analyzed available evidence to determine how these highly visible labels—which alert consumers to high levels of sugar, sodium, saturated fats, and trans fats—impact purchasing behaviors and overall public health variables. The core findings of the review indicate that clear, front-of-package warnings successfully disrupt automatic shopping habits. By providing immediate, easy-to-understand nutritional assessments, the labels help consumers navigate away from ultra-processed foods and toward healthier alternatives. The study assessed shifts in dietary patterns and the nutritional quality of purchased goods following the policy's rollout. A limitation of scoping reviews on public policy is that it can be challenging to isolate the effect of the labels from other concurrent health campaigns or economic factors influencing food prices and availability.
Scientists have identified a specific mechanism linking the gut microbiome to age-related cognitive decline. In a study using mice, researchers discovered that as the animals aged, their gut microbiome changed, leading to an accumulation of a bacterium called *Parabacteroides goldsteinii*. This bacterium produces compounds that activate an inflammatory receptor (GPR84) on peripheral immune cells. This inflammation, in turn, impairs the function of the vagus nerve, a critical communication highway connecting the gut to the brain. The weakened signal from the gut resulted in reduced neuronal activity in the hippocampus, the brain's memory center, leading to memory deficits in the aged mice. Crucially, the researchers were able to reverse this memory loss by intervening at several points in the pathway: using bacteriophages to target the specific bacteria, chemically blocking the GPR84 receptor, or directly stimulating the vagus nerve.